Stina Syvänen
Professor at Department of Public Health and Caring Sciences; Molecular Geriatrics / Rudbeck laboratory
- Telephone:
- +46 18 471 34 05
- E-mail:
- stina.syvanen@uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
- Postal address:
- Rudbecklaboratoriet
751 85 Uppsala
More information is available to staff who log in.
Research
Our research is focused on understanding the molecular mechanisms behind Alzheimer's disease and other types of dementia. We have generated antibodies that bind specifically to different forms of Aβ or α-synuclein. Some of the antibodies have also been modified to bind the transferrin receptor (TfR), which is normally involved in iron transport into the brain. The interaction with TfR works like a molecular Trojan horse, which transports the antibody into the brain, where it can bind to its target. This modification increases antibody brain concentration up to 100-fold. These bispecific antibodies have been explored as novel PET radioligands and as immunotherapeutics.
In parallel with the development of brain penetrant antibodies we study changes in the blood-brain barrier (BBB) during neurodegeneration. We also use small molecule PET radioligands to investigate pathology in the ageing brain focusing mainly on protein deposits, neuroinflammation and synaptic dysfunction.
.Publications
Selection of publications
- Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody (2023)
- Brain pharmacokinetics of mono- and bispecific amyloid-beta antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis (2022)
- 11C-PiB and 124I-antibody PET provide differing estimates of brain amyloid-β after therapeutic intervention (2022)
- PET Imaging in Preclinical Anti-Aβ Drug Development (2022)
- Engineered antibodies (2019)
- Efficient clearence of A beta protofibrils in A beta PP-transgenic mice treated with a brain-penetrating bifunctional antibody (2018)
- Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease (2016)
- Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport (2009)
- On the rate and extent of drug delivery to the brain (2008)
- Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET (2006)
Recent publications
- Comparing in vitro affinity measurements of antibodies to TfR1 (2024)
- Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging (2024)
- Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion (2024)
- Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody (2024)
- Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET (2024)
All publications
Articles
- Comparing in vitro affinity measurements of antibodies to TfR1 (2024)
- Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging (2024)
- Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion (2024)
- Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody (2024)
- Synthesis and evaluation of fluorine-18 labelled tetrazines as pre-targeting imaging agents for PET (2024)
- Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau (2023)
- Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody (2023)
- Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer's disease (2023)
- Pretargeted imaging beyond the blood-brain barrier (2023)
- Synaptic density in aging mice measured by [18F]SynVesT-1 PET (2023)
- Cryo-EM of Aβ fibrils from mouse models find tg-APPArcSwe fibrils resemble those found in patients with sporadic Alzheimer's disease (2023)
- Development of the First Tritiated Tetrazine (2022)
- ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer's disease with a bispecific, brain-penetrating fusion protein (2022)
- Introducing or removing heparan sulfate binding sites does not alter brain uptake of the blood-brain barrier shuttle scFv8D3 (2022)
- Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-A beta-Affibodies (2022)
- Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's A beta amyloidosis (2022)
- Brain pharmacokinetics of mono- and bispecific amyloid-beta antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis (2022)
- Advances in the development of new biomarkers for Alzheimer's disease (2022)
- 11C-PiB and 124I-antibody PET provide differing estimates of brain amyloid-β after therapeutic intervention (2022)
- Passive and receptor mediated brain delivery of an anti-GFAP nanobody (2022)
- A Brain-Targeting Bispecific-Multivalent Antibody Clears Soluble Amyloid-Beta Aggregates in Alzheimer's Disease Mice (2022)
- Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease (2022)
- Reduction of alpha SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody (2022)
- In vivo imaging of alpha-synuclein with antibody-based PET (2022)
- Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging (2022)
- Professor Margareta Hammarlund-Udenaes (2022)
- PET Imaging in Preclinical Anti-Aβ Drug Development (2022)
- Pretargeted Imaging beyond the Blood-Brain Barrier-Utopia or Feasible? (2022)
- Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size (2021)
- Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease (2021)
- Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide (2021)
- Enhanced neprilysin-mediated degradation of hippocampal A beta 42 with a somatostatin peptide that enters the brain (2021)
- In vivo imaging of synaptic density with [C-11]UCB-J PET in two mouse models of neurodegenerative disease (2021)
- SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-beta antibody in a mouse model of Alzheimer's disease (2020)
- Chemical imaging of evolving amyloid plaque pathology and associated A β peptide aggregation in a transgenic mouse model of Alzheimer's disease (2020)
- Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle. (2020)
- Blocking of efflux transporters in rats improves translational validation of brain radioligands (2020)
- Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-β in Brain (2020)
- High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain (2019)
- Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology (2019)
- Engineered antibodies (2019)
- Long-Term Effects of Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease (2019)
- P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling (2018)
- [F-18]Tetrazine-trans-cyclooctene mediated labelling of antibodies for PET imaging of amyloid-beta (2018)
- Blood-Brain Barrier Integrity in a Mouse Model of Alzheimer’s Disease With or Without Acute 3D6 Immunotherapy (2018)
- Intact blood-brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha-synuclein pathology (2018)
- Antibody-Based In Vivo PET Imaging Detects Amyloid-beta Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition (2018)
- Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease (2018)
- Efficient clearence of A beta protofibrils in A beta PP-transgenic mice treated with a brain-penetrating bifunctional antibody (2018)
- Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([18F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression (2018)
- Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [(11)C]ABP688 PET imaging and ex vivo immunoblotting (2017)
- Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells (2017)
- Combined PET and microdialysis for in vivo estimation of drug blood-brain barrier transport and brain unbound concentrations (2017)
- Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor (2017)
- Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry (2017)
- Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-beta (2017)
- Efficient clearance of Amyloid-beta protofibrils in APP-transgenic mice treated with a brain penetrating bifunctional antibody (2017)
- Cationization increases brain distribution of an amyloid-beta protofibril selective F(ab')2 fragment (2017)
- Antibody-based PET radioligands for imaging of amyloid-beta protofibrils (2017)
- A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging (2017)
- Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry (2016)
- Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease (2016)
- (R)-[(11)C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance (2014)
- Mechanism-Based Evaluation of Codeine Toxicity in Children (2014)
- Molecular Imaging of Inflammation Reveals Differences Between Drug-Resistant and Drug-Sensitive Animals in a Chronic Model of Temporal Lobe Epilepsy (2014)
- Specific Uptake of an Amyloid-beta Protofibril-Binding Antibody-Tracer in A beta PP Transgenic Mouse Brain (2013)
- Advances in PET Imaging of P-Glycoprotein Function at the Blood-Brain Barrier. (2013)
- [C-11]quinidine and [C-11]laniquidar PET imaging in a chronic rodent epilepsy model (2013)
- [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein. (2012)
- Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood--brain barriers studied with (R)-[11C]verapamil positron emission tomography. (2012)
- Altered GABAA Receptor Density and Unaltered Blood-Brain Barrier Transport in a Kainate Model of Epilepsy (2012)
- Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate. (2012)
- [11C]phenytoin revisited (2012)
- Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil. (2012)
- Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography (2011)
- (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. (2011)
- Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs (2010)
- Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport (2009)
- A computerized Infusion Pump for control of tissue tracer concentration during Positron Emission Tomography in vivo Pharmacokinetic/Pharmacodynamic measurements (2008)
- On the rate and extent of drug delivery to the brain (2008)
- Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier (2008)
- Effect on [11C]DASB binding after tranylcypromine-induced increase in serotonin concentration (2007)
- PET-evaluated transport of [11C]hydroxyurea across the rat blood-brain barrier - (2007)
- Synthesis of two potential NK1-receptor ligands using [1-11C]ethyl iodide and [1-11C]propyl iodide and initial PET-imaging (2007)
- Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data (2006)
- Predicting brain concentrations of drug using positron emission tomography and venous input (2006)
- Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET (2006)
- Pharmacokinetic consequences of active drug efflux at the blood-brain barrier (2006)
- Stronger affinity to Transferrin receptor enhances detection of amyloid-β pathology with bispecific antibody radioligands at a tracer dose
- Evaluation of valency effects on TfR-mediated brain delivery in vivo
- Single domain antibody conjugated to Aβ-binding scFv penetrates BBB via TfR to interact with Aβ
- Therapeutic and diagnostic potential of a multivalent antibody against soluble amyloid-beta aggregates
- The Uppsala APP mutation promotes wildtype Aβ aggregation and deposition in vivo
- Transgenic mice harboring the Uppsala APP mutation display altered APP processing and accelerated Aβ42 pathology with distinct structural features
- Reduced neonatal Fc receptor binding increases clearance and brain-to-blood ratio of a brain penetrating amyloid-β antibody
- Aβ targeting ImmunoPET
- [11C]PiB binding after treatment with an amyloid-beta antibody
- Synaptic density in aging mice measured by [18F]SynVesT-1 PET
Books
- Blood-Brain Barrier Transport (2008)
- Active transporters in the blood-brain barrier: A simulation study and a Positrion Emmission Tomography study. (2005)